Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun:300:113853.
doi: 10.1016/j.psychres.2021.113853. Epub 2021 Mar 4.

Specialty knowledge and competency standards for pharmacotherapy for adult obsessive-compulsive disorder

Affiliations

Specialty knowledge and competency standards for pharmacotherapy for adult obsessive-compulsive disorder

Christopher Pittenger et al. Psychiatry Res. 2021 Jun.

Abstract

Obsessive-compulsive disorder (OCD) affects approximately one person in 40 and causes substantial suffering. Evidence-based treatments can benefit many; however, optimal treatment can be difficult to access. Diagnosis is frequently delayed, and pharmacological and psychotherapeutic interventions often fail to follow evidence-based guidelines. To ameliorate this distressing situation, the International OCD Accreditation Task Force of the Canadian Institute for Obsessive-Compulsive Disorders has developed knowledge and competency standards for specialized treatments for OCD through the lifespan. These are foundational to evidence-based practice and will form the basis for upcoming ATF development of certification/accreditation programs. Here, we present specialty standards for the pharmacological treatment of adult OCD. We emphasize the importance of integrating pharmacotherapy with clear diagnosis, appreciation of complicating factors, and evidence-based cognitive behavioral therapy. Clear evidence exists to inform first- and second-line pharmacological treatments. In disease refractory to these initial efforts, multiple strategies have been investigated, but the evidence is more equivocal. These standards summarize this limited evidence to give the specialist practitioner a solid basis on which to make difficult decisions in complex cases. It is hoped that further research will lead to development of a clear, multi-step treatment algorithm to support each step in clinical decision-making.

Keywords: Obsessive-compulsive disorder (OCD); augmentation; comorbidity; pharmacotherapy; selective serotonin reuptake inhibitors (SSRIs); treatment.

PubMed Disclaimer

Conflict of interest statement

The following professionals are deemed by the ATF to be “opposed reviewers” of the phase two submitted papers due to conflict of interest (prior involvement in the project, competing interests, or personal relationship)

Jon Abramowitz, Martin Antony, Cheryl Carmin, David A. Clark, Martin E. Franklin, Jennifer B. Freeman, Naomi Fineberg, Randi McCabe, Josee Menchon, Christine Purdon, Neil Rector, Peggy Richter, Karen Rowa, Gail Steketee, Evelyn Stewart, Noam Soreni, Joseph Zohar

Similar articles

Cited by

References

    1. Aboujaoude E, Barry JJ, Gamel N, 2009. Memantine augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial. J. Clin. Psychopharmacol 29, 51–55. - PubMed
    1. Abramowitz JS, 2017. Exposure and response prevention in OCD, in: Pittenger C. (Ed.), Obsessive-Compulsive Disorder: Phenomenology, Pathophysiology, and Treatment. Oxford University Press, New York.
    1. Abramowitz JS, Deacon BJ, Olatunji BO, Wheaton MG, Berman NC, Losardo D, Timpano KR, McGrath PB, Riemann BC, Adams T, Bjøorgvinsson T, Storch EA, Hale LR, 2010. Assessment of obsessive-compulsive symptom dimensions: Development and evaluation of the Dimensional Obsessive-Compulsive Scale. Psychol. Assess 22, 180–198. - PubMed
    1. Abramowitz J, Foa E, 2000. Does comorbid major depressive disorder influence outcome of exposure and response prevention for OCD? Behav. Ther 31, 795–800.
    1. Abramowitz JS, Lackey GR, Wheaton MG, 2009. Obsessive-compulsive symptoms: The contribution of obsessional beliefs and experiential avoidance. J. Anxiety. Disord 23, 160–166. - PubMed

Substances